| 中文名称: | Dabuzalgron | ||||
|---|---|---|---|---|---|
| 英文名称: | Dabuzalgron | ||||
| 别名: | 达布扎琼;N-[6-氯-3-[(4,5-二氢-1H-咪唑-2-基)甲氧基]-2-甲基苯基]甲磺酰胺 Ro 115-1240 | ||||
| CAS No: | 219311-44-1 | 分子式: | C12H16ClN3O3S | 分子量: | 317.79 |
| CAS No: | 219311-44-1 | ||||
| 分子式: | C12H16ClN3O3S | ||||
| 分子量: | 317.79 | ||||
基本信息
|
产品编号： |
D10764 |
||||
|
产品名称： |
Dabuzalgron |
||||
|
CAS: |
219311-44-1 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量： |
317.79 |
-20℃ |
1个月 |
||
|
化学名： |
N-(6-Chloro-3-((4,5-dihydro-1H-imidazol-2-yl)methoxy)-2-methylphenyl)methanesulfonamide |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
3.1467mL |
15.7337mL |
31.4673mL |
|
5mM |
0.6293mL |
3.1467mL |
6.2935mL |
|
10mM |
0.3147mL |
1.5734mL |
3.1467mL |
生物活性
|
产品描述 |
一种口服活性的，选择性的 α-1A 肾上腺素能受体激动剂，动物模型中，用于缓解尿失禁。 |
|
|
靶点 |
α-1A adrenergic receptor |
|
|
体外研究 |
Dabuzalgron treatment increases ERK phosphorylation in a dose-dependent fashion with an EC50 of 4.8μM.ERK1/2 activation contributes to the cardioprotective effects of Dabuzalgron.Dabuzalgron (10μM;4 hours) protects NRVMs from cell death due to Doxorubicin (DOX).Activation of the α1A-AR with Dabuzalgron (10μM;4 hours) mitigates the detrimental effects of DOX on mitochondrial membrane potential and abrogates the activation of important elements of the apoptotic response to mitochondrial damage. Western Blot Analysis |
|
|
Cell Line: |
Neonatal rat ventricular myocytes (NRVMs) |
|
|
Concentration: |
0.1μM,1μM,10μM and 100μM |
|
|
Incubation Time: |
15 minutes |
|
|
Result: |
Increased ERK phosphorylation in a dose-dependent fashion with an EC50 of 4.8μM. |
|
|
体内研究 |
Dabuzalgron (10μg/kg;oral gavage;twice daily;for 7 days;C57Bl6J wild-type or α1A-AR knockout mice) treatment protects against DOX cardiotoxicity by activating the α1A-AR.Dabuzalgron protects against the reduction in transcripts related to mitochondrial function,up-regulates PGC1α,preserves ATP content,and reduces oxidative stress in the hearts of mice treated with DOX. |
|
|
Animal Model: |
Male C57Bl6J wild-type (WT) or α1A-AR knockout (AKO) mice (8-12-week-old) injected with Doxorubicin (DOX) |
|
|
Dosage: |
10μg/kg |
|
|
Administration: |
Oral gavage;twice daily;for 7 days |
|
|
Result: |
Preserved contractile function and reduced fibrosis after DOX administration.AKO mice treated with DOX had worse survival and more profoundly impaired contractile function than WT mice.Protected against the reduction in transcripts related to mitochondrial function,preserved ATP content,and reduced oxidative stress in the hearts of mice treated with DOX. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
